Inclusion of Under-Represented Racial and Ethnic Groups in Cardiovascular Clinical Trials

被引:21
|
作者
Vilcant, Viliane [1 ]
Ceron, Carlos [1 ]
Verma, Gagan [2 ]
Zeltser, Roman [1 ,2 ]
Makaryus, Amgad N. [1 ,2 ]
机构
[1] Nassau Univ Med Ctr, E Meadow, NY 11554 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11549 USA
来源
HEART LUNG AND CIRCULATION | 2022年 / 31卷 / 09期
关键词
Racial minorities; Ethnic minorities; Underrepresentation; Race; Ethnicity; Cardiology; Trials; DISPARITIES; ENROLLMENT; MINORITIES; MORTALITY; HEALTH;
D O I
10.1016/j.hlc.2022.06.668
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Non-White racial and ethnic groups have been traditionally under-represented for decades in the field of cardiology, specifically in cardiovascular research studies. This underrepresentation has occurred despite the fact that these racial and ethnic groups have been shown to be at increased risk of cardiovascular disease (CVD). Methods To assess the trend of representation in mainstream landmark cardiovascular trials, we performed a review of major cardiovascular trials published between 1986 and 2019. Mainstream landmark trials were selected as classified by established cardiology standards. The reported numbers of racial and ethnic participants were assessed within these categorised cardiovascular trials over a continuous time period. Results A total of 1,138,683 patients were assessed from 153 randomised clinical trials. Of these trials, only 56% (n=86) reported information about race. Of note, 99% (n=152) of these trials reported gender. About three-quarters of the trials (77%) were undertaken at least partly in the United States (US). Our results show that the percentage of non-White participants in clinical trials was not significantly different over time (p=0.85), suggesting no significant improvement in non-White racial/ethnic representation. Further analysis of only the US inclusive trials (n=20) also showed no significant improvement in representation (p=0.38). Conclusion Only about half of all major cardiovascular landmark trials reported any racial or ethnic information, despite more recent calls over the last 5-10 years for diversity and representation in cardiovascular research studies. Additionally, no significant improvement in inclusion of traditionally under-represented racial and ethnic groups (UREGs) in these trials has occurred over time. Our analysis shows that there is still major work to be done to foster better representation and evaluation of the UREG population in cardiovascular trials.
引用
收藏
页码:1263 / 1268
页数:6
相关论文
共 50 条
  • [41] Thriving as members of under-represented groups in pharmacology-related careers
    Momplaisir, Nathalie L.
    Delatte, Marcus
    Puthenveedu, Manojkumar A.
    Wilkerson, Jenny
    Edwards, Emmeline
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (12) : 849 - 856
  • [42] Condyloma acuminata in under-represented groups: an All of Us database analysis
    Moseley, Isabelle
    Ragi, Sara D.
    Ouellette, Samantha
    Rao, Babar
    SEXUALLY TRANSMITTED INFECTIONS, 2022, 98 (08) : 620 - 621
  • [43] Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials
    Meyers, Daniel E.
    Rittberg, Rebekah
    Dawe, David E.
    Banerji, Shantanu
    CURRENT ONCOLOGY, 2024, 31 (09) : 5498 - 5515
  • [44] ADVENTURES IN ENGINEERING - A UNIQUE PROGRAM TO ATTRACT UNDER-REPRESENTED GROUPS TO ENGINEERING
    MCCULLOUGH, CL
    CRULL, M
    THOMAS, D
    IEEE TRANSACTIONS ON EDUCATION, 1994, 37 (01) : 3 - 7
  • [45] Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
    Chua Jr, Alfredo V.
    Delmerico, Jennifer
    Sheng, Haiyang
    Huang, Xin-Wei
    Liang, Emily
    Yan, Li
    Gandhi, Shipra
    Puzanov, Igor
    Jain, Prantesh
    Sakoda, Lori C.
    Morrow, Gary R.
    Ambrosone, Christine B.
    Kamen, Charles
    Yao, Song
    JCO ONCOLOGY PRACTICE, 2025, 21 (03)
  • [46] Accrual of under-represented minority women to breast cancer clinical trials in Inland Empire, California.
    Yuan, Yuan
    Uppala, Padma Tadi
    Lum, Sharon S.
    Morgan, John W.
    Garberoglio, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [47] Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups
    Asmann, Y.
    Parikh, K.
    Borad, M.
    Bergsagel, L.
    Mansfield, A. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S274 - S275
  • [48] Minorities are under-reported and females are under-represented in stroke motor recovery trials
    Hassani, Sara
    Dargham, Tarek Bou
    Cantrell, Sarah
    Ikramuddin, Salman
    Feng, Wuwei
    TOPICS IN STROKE REHABILITATION, 2025, 32 (02) : 208 - 212
  • [49] Women, Ethnic, and Racial Groups Are Underreported and Underrepresented in Atrial Fibrillation Clinical Trials
    Wang, Paul C.
    Rice, Eli C.
    Stafford, Randall S.
    Lewis, Eldrin
    Wang, Paul J.
    CIRCULATION, 2021, 144
  • [50] Generalizing the Results of Clinical Trials if Participants Are Not From Diverse Racial and Ethnic Groups
    Tur, Carmen
    Carvajal, Rene
    Otero-Romero, Susana
    Tintore, Mar
    NEUROLOGY, 2024, 103 (03)